Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is -20.56% lower on its value in year-to-date trading and has touched a low of $29.59 and a high of $60.37 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RARE stock was last observed hovering at around $35.06 in the last trading session, with the day’s loss setting it -1.64%.
Currently trading at $33.42, the stock is -8.08% and -10.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.77 million and changing -4.68% at the moment leaves the stock -27.83% off its SMA200. RARE registered -21.82% loss for a year compared to 6-month loss of -34.46%.
The stock witnessed a 3.98% gain in the last 1 month and extending the period to 3 months gives it a -26.34%, and is -14.26% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.61% over the week and 5.45% over the month.
Ultragenyx Pharmaceutical Inc (RARE) has around 1294 employees, a market worth around $3.14B and $590.69M in sales. Profit margin for the company is -93.04%. Distance from 52-week low is 12.94% and -44.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.73%).
The EPS is expected to grow by 20.82% this year
The shares outstanding are 93.90M, and float is at 87.94M with Short Float at 6.20%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 9.78 million shares valued at $401.98 million. The investor’s holdings represent 11.2964 of the RARE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.6 million shares valued at $230.3 million to account for 6.4718 of the shares outstanding. The other top investors are SANDS CAPITAL MANAGEMENT, LLC which holds 5.35 million shares representing 6.1847 and valued at over $220.08 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.2623 of the shares totaling 4.56 million with a market value of $187.26 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
The most recent transaction is an insider sale by Crombez Eric, the company’s EVP and Chief Medical Officer. SEC filings show that Crombez Eric sold 520 shares of the company’s common stock on May 05 ’25 at a price of $39.24 per share for a total of $20405.0. Following the sale, the insider now owns 71530.0 shares.
Ultragenyx Pharmaceutical Inc disclosed in a document filed with the SEC on Apr 21 ’25 that Crombez Eric (EVP and Chief Medical Officer) sold a total of 242 shares of the company’s common stock. The trade occurred on Apr 21 ’25 and was made at $35.11 per share for $8497.0. Following the transaction, the insider now directly holds 71680.0 shares of the RARE stock.
Still, SEC filings show that on Mar 06 ’25, Horn Howard (Chief Financial Officer) disposed off 1,785 shares at an average price of $40.40 for $72114.0. The insider now directly holds 106,169 shares of Ultragenyx Pharmaceutical Inc (RARE).
